| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;103:1709.)
© 2001 American Heart Association, Inc.
Basic Science Reports |
From the Departments of Pathology and Microbiology-Immunology and the Feinberg Cardiovascular Research Institute, Northwestern University Medical School, Chicago, Ill.
Correspondence to David M. Engman, Northwestern University Medical School, Department of Pathology, 303 E Chicago Ave, Ward 6-175, Chicago, IL 60611. E-mail d-engman{at}nwu.edu
BackgroundAutoimmunity to cardiac antigens, in particular cardiac myosin, has been observed in humans with myocarditis and in animals with experimental inflammatory heart disease. Current treatments for myocarditis are in many cases immunosuppressive and might lead to increased cardiac damage by reducing host defenses against infectious agents. Therefore, we sought to develop an antigen-specific approach to inhibit autoimmunity in mice with myosin-induced experimental autoimmune myocarditis.
Methods and ResultsSyngeneic splenocytes, coupled with cardiac myosin by use of ethylene carbodiimide, were administered intravenously before disease induction, and the effects of this peripheral tolerization on myosin-induced myocarditis were assessed. This antigen-specific immunotherapy significantly reduced both the incidence and severity of myocarditis, with the prevention of myocyte necrosis, mononuclear cell infiltration, and fibrosis. Myosin-specific delayed-type hypersensitivity and antibody production were significantly reduced, demonstrating that peripheral tolerance affected both T- and B-cell responsiveness to the autoantigen.
ConclusionsThese results suggest that the induction of antigen-specific peripheral immune tolerance may be an effective approach for the treatment of myocarditides with autoimmune involvement.
Key Words: myocarditis myosin lymphocytes
This article has been cited by other articles:
![]() |
C. Meagher, Q. Tang, B. T. Fife, H. Bour-Jordan, J. Wu, C. Pardoux, M. Bi, K. Melli, and J. A. Bluestone Spontaneous Development of a Pancreatic Exocrine Disease in CD28-Deficient NOD Mice J. Immunol., June 15, 2008; 180(12): 7793 - 7803. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Marty, S. Dirnhofer, N. Mauermann, S. Schweikert, S. Akira, L. Hunziker, J. M. Penninger, and U. Eriksson MyD88 Signaling Controls Autoimmune Myocarditis Induction Circulation, January 17, 2006; 113(2): 258 - 265. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, J. S. Heuser, S. D. Kosanke, M. Hemric, and M. W. Cunningham Protection against Experimental Autoimmune Myocarditis Is Mediated by Interleukin-10-Producing T Cells that Are Controlled by Dendritic Cells Am. J. Pathol., July 1, 2005; 167(1): 5 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Leon, M. D. Daniels, K. M. Toriello, K. Wang, and D. M. Engman A Cardiac Myosin-Specific Autoimmune Response Is Induced by Immunization with Trypanosoma cruzi Proteins Infect. Immun., June 1, 2004; 72(6): 3410 - 3417. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Leon, K. Wang, and D. M. Engman Myosin Autoimmunity Is Not Essential for Cardiac Inflammation in Acute Chagas' Disease J. Immunol., October 15, 2003; 171(8): 4271 - 4277. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Godsel, J. S. Leon, K. Wang, J. L. Fornek, A. Molteni, and D. M. Engman Captopril Prevents Experimental Autoimmune Myocarditis J. Immunol., July 1, 2003; 171(1): 346 - 352. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Leon, L. M. Godsel, K. Wang, and D. M. Engman Cardiac Myosin Autoimmunity in Acute Chagas' Heart Disease Infect. Immun., September 1, 2001; 69(9): 5643 - 5649. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |